Solara Active Pharma Sciences Ltd announced the successful completion EU-GMP Inspection, carried out jointly by the SUKL, Ministry of Health of the Czech Republic and INFARMED, Portugal at the multi-product manufacturing facility at Cuddalore.
According to the findings of a new Future Market Insights (FMI) report, the global Ibuprofen API Market crossed US$ 626.2 Million in 2022 and is expected to grow at a CAGR of 3% to reach US$ 772.2 Million by 2029. The key drivers of the Ibuprofen API market are the ongoing need for low-cost nonsteroidal anti-inflamm.
USFDA clears Solara Active's Visakhapatnam facility.
The US Food and Drug Administration has cleared Solara Active Pharma Sciences Ltd's new multipurpose active pharmaceutical ingredient manufacturing facility at Visakhapatnam, Andhra Pradesh, with no observation, the company said in an exchange filing.
Solara Active Pharma Sciences Ltd today announced that its new state-of-the-art multipurpose API manufacturing facility at Visakhapatnam, Andhra Pradesh completed successfully the inspection carried out by the US FDA.
Solara Active Pharma Sciences Limited has successfully completed the inspection carried out by the World Health Organization at its Cuddalore facility, Tamil Nadu between January 23 – 26, 2023.